TX-DEFI-SUMMIT
14.6.2021 02:17:13 CEST | Business Wire | Press release
The largest-ever dedicated conference focused specifically on decentralized finance starts today at 9am Pacific Time. DeFi Summit is a weeklong virtual event bringing together the builders and developers that make up the decentralized finance and non-fungible token community. Free to attend, talks and presentations will be held on a broad range of topics, including DEX, wallets, DAOs, NFTs, insurance, lending, and many more.
DeFi Summit 2021 Agenda:
Day 1 (Monday, June 14) – The summit starts with a full day focused on NFTs. Notable speakers include digital artists Pplpleasr and Matty Mo , Max Moore of Sotheby’s, and companies including Axie Infinity, Animoca Brands and Aavegotchi.
Day 2 (Tuesday, June 15) – A mystery billionaire investor is the special guest joining Polygon Power Hour alongside Stani Kulechov from Aave, Sandeep Naiwal from Polygon and Roc Zacharias from Quickswap. Stay tuned for Coinbase, Unicrypt, Finance.Vote, and YFDAI, plus an exciting panel featuring OG DeFi VCs Leslie Tam of GBV Capital, Miko Matsumura of Gumi Cryptos Capital, and Adrian Lai of Liquefy Labs.
Day 3 (Wednesday, June 16) – More experts from Chainlink, Cosmos, Luna, Stacks and OpenOcean speak on the second day. The DeFi trader roundtable features Boxmining , Cryptonauts and DeFi Summit co-founders Justin Wu and Michael Huynh .
Day 4 (Thursday, June 17) – Presented by Launchpool , DeFi Demo Day is a dedicated day-long event where startups demo their product or protocol, pitch their ideas, and share with the community. Projects to look out for include Parallel Finance , Pledge Finance , Akash Network and Mintlayer .
Day 5 (Friday, June 18) – #DeFiWeek wraps up with a Decentralized Afterparty and networking event in Decentraland. Sign up here.
About DeFi Summit
The first-ever DeFi Summit is the largest gathering of the decentralized finance community ever held, giving builders and developers a chance to meet, share ideas, and discuss the biggest issues affecting the world of DeFi. The free-to-all event includes presentations, roundtable discussions, demos, and workshops from some of the leading innovators in the industry. The virtual summit is held June 14-18, 2021 and includes attendees and participants from around the globe. Register to attend here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210613005041/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom